Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Fiche publication
Date publication
décembre 2020
Journal
The breast journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Pr PIVOT Xavier, Pr VELTEN Michel
Tous les auteurs :
Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, Petit T
Lien Pubmed
Résumé
Breast cancer is the most common cancer among women. Localized breast cancer treatments involve taxanes which are often responsible for acute peripheral neuropathy. The persistence of taxane-induced peripheral neuropathy (TIPN) is scarcely described among elderly women. A monocenter historical cohort study including all women over 65 years of age treated between 2001 and 2016 with a taxane-based chemotherapy for localized breast cancer was carried out at the Paul Strauss Regional Comprehensive Cancer Center. All cases included were followed up for at least 2 years, deaths from causes unrelated to TIPN were excluded. We report on the frequency and risk factors and establish a prognostic score of persistent Common Terminology Criteria for Adverse Events (CTCAE) grade 2 and 3 TIPN. Among the 302 included patients, 21% and 9% developed persistent TIPN of grade 2 and 3, respectively. Two patients died from complications of grade 3 TIPN. Risk factors of persistent grade 2 and higher neuropathy included age (P < .0001), body mass index (P < .0001), and diabetes (P = .0093). Persistent TIPN was more frequent with paclitaxel than docetaxel (OR = 5.43; P < .0001). Patients presenting all four major risk factors had a 97.2% probability of developing long-term symptoms against 1.2% for patients showing no risk factor. We therefore identified 3 prognostic groups. TIPN is a frequent and sometimes severe persistent side effect of breast cancer treatment among elderly women with a major impact on health-related quality of life. Chemotherapy regimens without taxane could therefore be a valid option in elderly patients with neurotoxicity risk factors.
Mots clés
breast neoplasms, neurotoxicity syndromes, peripheral nervous system diseases, prognostic score, taxoids
Référence
Breast J. 2020 Dec 11;: